CoChat
Sign Up
Cited by 174Thyroid Disorders and TreatmentsThyroid and Parathyroid SurgeryGrowth Hormone and Insulin-like Growth Factors

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Thyrotropin Suppression by Metformin

Vigersky, Robert A., Filmore-Nassar, Amy, Glass, Allan R.·2006·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2005-1210
Open this paper in CoChat — free account

Abstract

Context: Drug-drug interactions are common but often are discovered only long after initial drug release. Metformin has been available in the United States for 9 yr and elsewhere for many years, but as of yet there are no reports that the drug modifies thyroid hormone economy. Objective: The objective of the study was to describe the clinical and biochemical findings of four patients with chronic hypothyroidism, previously euthyroid on fixed doses of l-T4 for several years, in whom the metformin was initiated. Design: This was a retrospective review. Setting: The study was conducted at a tertiary care military hospital providing care to active-duty soldiers, sailors, and marines, retirees of the armed forces, and their eligible dependents. Participants: Four patients with chronic hypothyroidism who were placed on metformin participated in the study. Intervention, Main Outcome Measure: Serum TSH, free T4, and free T3 levels were measured during metformin treatment. Results: Initiation of treatment with metformin (three for diabetes mellitus and one for nonalcoholic steatohepatitis) caused suppression of TSH to subnormal levels without clinical symptoms of hyperthyroidism in any patients. There was no change in free T4 or free T3 in patient 1. Conclusions: No other potential causes of TSH suppression, including medication changes or interference in the TSH assay, could be identified. The mechanism of the fall in serum TSH in these four patients is unclear at this time. Should these findings be confirmed in larger prospective studies, metformin’s ability to suppress TSH without causing clinical or chemical hyperthyroidism might render this drug a useful adjunct to the treatment of patients with thyroid cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2005-1210

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 12 references

Cited by

Sorted by citations

Items 101–173 of 173

Related

See all

Metadata

Authors
Vigersky, R. A., Filmore-Nassar, A., & Glass, A. R.
Affiliations
Walter Reed National Military Medical Center (US)
Corresponding author
Vigersky, Robert A.
ORCID
Vigersky, Robert A.
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2006-01-01
Volume
91
Issue
1
Pages
225-227
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jc.2005-1210
OpenAlex
W1979756450
Cited by
174
References
12
Citations by year
2026: 1 · 2025: 8 · 2024: 6 · 2023: 6 · 2022: 13 · 2021: 8 · 2020: 6 · 2019: 9 · 2018: 8 · 2017: 16 · 2016: 7 · 2015: 12 · 2014: 14 · 2013: 15 · 2012: 10
FWCI
4.98
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Defense
  • U.S. Army
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
Keywords
metformin, TSH suppression, thyroid-stimulating hormone, drug-drug interactions, thyroid hormone levels, free thyroxine, free T3, nonalcoholic steatohepatitis, diabetes mellitus
MeSH terms
Aged, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Drug Interactions, Female, Goiter, Graves Disease, Humans, Hypoglycemic Agents, Hypothyroidism, Liver Function Tests, Male, Metformin, Middle Aged, Retrospective Studies, Thyroid Function Tests, Thyroidectomy, Thyrotropin, Triiodothyronine, Hashimoto Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review